Sensyne Health launches gestational diabetes monitoring technology

Replacing old-fashioned paper-based management of the condition, the technology comprises a smartphone application that connects to a wireless blood glucose monitor and sends patient glucose measurements, text descriptions and callback requests to a specialist hospital team.

Gestational diabetes consists of high blood sugar developing during pregnancy, which can potentially cause premature birth or stillbirth in rare circumstances.

Paul Drayson, chief executive of Sensyne Health, said: "The overwhelming positive response to GDm-Health from the NHS and from women with gestational diabetes is testament to its clinically led design and the fact it is technology that is addressing an area of urgent, clinical need. We look forward to its wider adoption in the coming months."

The product is currently available to pregnant women and their midwives at Oxford University Hospitals NHS Foundation Trust and Royal Berkshire NHS Foundation Trust, and three additional trusts will make the product available in the coming weeks.

The launch follows a 2-year clinical evaluation of 1,000 women in the NHS after development by London-listed Sensyne Health in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust.

Bini Ajay, consultant obstetrician & gynaecologist at Croydon Health Services NHS Trust, said: "We start our large pilot of GDm-Health in October and, having seen its success in other Trusts, hope our experience will inform a decision to endorse it for widespread NHS use."

Sensyne’s shares were up 1.30% at 195.00p at 1226 BST.